Marketing Funding. 5.2.1 Adolor Products in the United States. Subject to reconciliation ------------------------------------ as provided in Section 6.7.5, on an Adolor Product-by-Adolor Product basis, Adolor shall be responsible and pay for ** percent (**%) and GSK shall be responsible and pay for ** percent (**%) of the Marketing Expenses for each Adolor Product for Commercialization in the United States incurred from ** through the First Commercial Sale for such Adolor Product. Thereafter, Marketing Expenses for each Adolor Product shall be shared in accordance with the sharing of the Adolor Product Marketing Contribution for such Adolor Product as adjusted pursuant to Section 6.3.4. Notwithstanding the foregoing, if a ** Study for an Adolor Product is not commenced earlier than ** (**) years prior to the expiration of the Adolor Product Promotion Term and such ** Study has no applicability to a Collaboration Product in any Country in the ROW, Adolor shall be responsible and pay for ** (**%) of any such ** Study. 5.2.2 OBD Chronic Product in the United States. Subject to ---------------------------------------- reconciliation as provided in Section 6.7.5, Adolor shall be responsible and pay for ** percent (**%) and GSK shall be responsible and pay for ** percent (**%) of the Marketing Expenses in connection with the OBD Chronic Product for Commercialization in the United States incurred from the Effective Date through ** = Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. the First Commercial Sale for such OBD Chronic Product. Thereafter, Marketing Expenses for the OBD Chronic Product shall be shared in accordance with the sharing of the GI Product Marketing Contribution for such OBD Chronic Product as adjusted pursuant to Section 6.3.4. Notwithstanding the foregoing, upon notice by Adolor to GSK of a Royalty Conversion Election, GSK shall be solely responsible and pay for all Marketing Expenses relating to periods after such notice for the OBD Chronic Product for which the Royalty Conversion Election was made.
Appears in 5 contracts
Samples: Collaboration Agreement (Adolor Corp), Collaboration Agreement (Adolor Corp), Collaboration Agreement (Adolor Corp)